Bausch Investors Initially Pessimistic Following B+L Spinout

Bausch Health Drops 27% Following Q1 Earnings Call

With its IPO of Bausch + Lomb bringing in $630m in proceeds, Bausch Health is moving forward with its plan to use the eye care unit’s separation to pay down its remaining debt.

Bausch Healthcare
Bausch Health began its new era as the B+L spinout became official • Source: Shutterstock

Following several years of preparation and build-up of anticipation, the Bausch Health Companies Inc. split went into effect on 10 May, with the closing of a $630m initial public offering for Bausch + Lomb Inc., effectively separating the eye care unit from the rest of the business. Bausch executives have pledged that the spinout of B+L will unlock the eye care business’s value and provide funding to pay down Bausch Health’s considerable debt, dating back to its hectic deal-making days as Valeant.

Bausch Health, which now will be led by incoming CEO Thomas Appio as his predecessor Joseph Papa moves over to B+L, also presented its first quarter 2022 sales and earnings...

More from Earnings

More from Business